Sign up to save your podcasts
Or
Share Yasha Modi, MD / Christina Y. Weng, MD, MBA - Weighing Out the Risks and Benefits of Intravitreal Anti-VEGF Injections for nAMD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Yasha Modi, MD / Christina Y. Weng, MD, MBA - Weighing Out the Risks and Benefits of Intravitreal Anti-VEGF Injections for nAMD
Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.
View all episodes
By Answers in CMEPlease visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.